Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Latigo Biotherapeutics, Inc. (LTGO)

Latigo Biotherapeutics names Todd Smith CEO; Q3 net loss narrows to $20.9 million

Positive Impact 4 of 5 leadership Written later

Latigo Biotherapeutics reported a third-quarter 2026 net loss of $20.9 million, down from $24.8 million a year earlier, and cash of $401.2 million that the company expects will fund operations into 2029. The company also said Todd Smith became president and CEO effective November 3, 2026, replacing Nima Farzan, who also resigned from the board.

Key points

  • Q3 2026 net loss was $20.9 million, versus $24.8 million in Q3 2025; R&D expenses fell to $17.5 million from $22.1 million, while G&A rose to $5.4 million from $2.6 million.
  • Cash and cash equivalents were $401.2 million as of September 30, 2026, expected to fund current operating plans into 2029.
  • Todd Smith became CEO effective November 3, 2026, with a $775,000 base salary, a 70% target cash incentive, and an option award with a $20 million grant-date fair value.
  • Nima Farzan will remain an employee through January 1, 2027, receive his 2026 bonus at 100% of target, and then serve as a consultant through December 31, 2027.

The filing

CompanyLatigo Biotherapeutics, Inc. (LTGO)
Form8-K, current report
Filed with the SECNov 5, 2026, 7:05 AM ET
Accession number0001193125-26-448537

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.